中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

151 records (took 0.04 seconds)

    MODIFIED HUMAN HEMOGLOBIN, BLOOD SUBSTITUTES CONTAINING THE SAME, AND VECTORS FOR EXPRESSING THE MODIFIED HEMOGLOBIN
    72.
    发明申请
    MODIFIED HUMAN HEMOGLOBIN, BLOOD SUBSTITUTES CONTAINING THE SAME, AND VECTORS FOR EXPRESSING THE MODIFIED HEMOGLOBIN 审中-公开
    修饰人类血红蛋白，含有其的血液替代物，以及用于表达改性的HEMOGLOBIN的载体

    公开(公告)号：WO1991019505A1

    公开(公告)日：1991-12-26

    申请号：PCT/US1991004156

    申请日：1991-06-20

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  FRONTICELLI, Clara ,  BUCCI, Enrico ,  BRINIGAR, William

    IPC: A61K35/14

    CPC classification number: C07K14/805 ,  A61K38/00

    Abstract: The invention relates to modified beta -chains of human hemoglobin having an oxygen binding affinity equal to or less than natural human hemoglobin and preferably has at least one chloride binding site not present in beta -chain of natural human hemoglobin. Examples of the modified beta -chain of human hemoglobin include the following site specific mutants: 1) NA1 (1) Val Met; delete NA2 (2) His, 2) HCl (144) Lys Arg, 3) NA1 (1) Val Met; NA2 (2) His deleted; HCl (144) Lys Arg, 4) NA1 (1) Val Met; NA2 (2) His deleted; E20 (76) Ala Lys, 5) NA1 (1) Val Met; NA2 (2) His deleted; E20 (76) Ala Lys; HCl (144) Lys Arg, 6) NA3 (3) Leu Glu or Asp, (7) A1 (4) Thr Glu or Asp, 8) A2 (5) Pro Asp or Glu; 9) A2 (5) Pro Gly, Ala or an amino acid having greater backbone flexibility, 10) E13 (69) Gly Gly or Asp, 11) E14 (70) Ala Thr or Ser, 12) E19 (75) Leu Cys or Met, 13) E20 (76) Ala Arg, His, or Lys, 14) NA1 (1) Val Met or Leu, 15) NA2 (2) His Leu, Tyr or Asp, 16) NA1 (1) Val, NA2 (2) His Met-Leu, Met-Asp, Met-Tyr, Leu-Leu, Leu-Asp or Leu-Tyr.

    Abstract translation: 本发明涉及具有等于或小于天然人血红蛋白的氧结合亲和力的人血红蛋白的修饰的β-链，并且优选具有至少一个不存在于天然人血红蛋白的β链中的氯化物结合位点。 人血红蛋白修饰的β-链的实例包括以下位点特异性突变体：1）NA1（1）Val Met; 删除NA2（2）His，2）HCl（144）Lys Arg，3）NA1（1）Val Met; NA2（2）他删除; HCl（144）Lys Arg，4）NA1（1）Val Met; NA2（2）他删除; E20（76）Ala Lys，5）NA1（1）Val Met; NA2（2）他删除; E20（76）Ala Lys; HCl（144）Lys Arg，6）NA3（3）Leu Glu或Asp，（7）A1（4）Thr Glu或Asp，8）A2（5）Pro Asp或Glu; 9）A2（5）Pro Gly，Ala或具有较大骨架柔性的氨基酸，10）E13（69）Gly Gly或Asp，11）E14（70）Ala Thr或Ser，12）E19（75）Leu Cys或 Met，13）E20（76）Ala Arg，His或Lys 14）NA1（1）Val Met或Leu 15）NA2（2）His Leu，Tyr或Asp，16）NA1（1）Val，NA2 2）他的Met-Leu，Met-Asp，Met-Tyr，Leu-Leu，Leu-Asp或Leu-Tyr。

    SELF-EMULSIFYING GLASSES
    73.
    发明申请
    SELF-EMULSIFYING GLASSES 审中-公开
    自我发光玻璃

    公开(公告)号：WO1991018613A1

    公开(公告)日：1991-12-12

    申请号：PCT/US1991003864

    申请日：1991-05-31

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC. ,  SHIVELY, Merrick, L.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC.

    IPC: A61K31/74

    CPC classification number: A21D10/002 ,  A21D2/18 ,  A23D7/00 ,  A61K8/06 ,  A61K8/066 ,  A61K9/107 ,  A61Q19/00

    Abstract: The present invention provides compositions and method for the preparation of emulsions and multiple emulsions. Specifically, the invention provides solids which are self-emulsifying glasses which, on contact with a sufficient amount of an aqueous phase, form emulsions or multiple emulsions without input of emulsive mixing. Emulsions and multiple emulsions produced from the self-emulsifying glasses are encompassed by this invention. The self-emulsifying glasses are prepared from certain matrix compounds and an oleaginous material by a solvent method. The glass results from removal of solvent from a combination of matrix compound, oleaginous material and a solvent which dissolves substantially all of the matrix compound. Multiple emulsions result from glasses in which the oleaginous phase is a primary, e.g. water-in-oil emulsion. The glasses and emulsions produced therefrom are particularly useful pharmaceutical, food and cosmetic applications.

    Abstract translation: 本发明提供了制备乳液和多重乳液的组合物和方法。 具体地说，本发明提供了自身乳化玻璃的固体，它们在与足量的水相接触时形成乳液或多重乳液而不输入乳化混合物。 由自乳化玻璃制备的乳液和多重乳液包括在本发明中。 自乳化玻璃由某些基质化合物和含油材料通过溶剂法制备。 该玻璃是从基质化合物，含油材料和基本上全部基质化合物溶解的溶剂的组合中除去溶剂。 多重乳液由其中油性相为主要的眼镜产生。 油包水乳液。 由此制备的眼镜和乳液是特别有用的药物，食品和化妆品应用。

    SYNTHETIC SENESCENT CELL ANTIGEN
    74.
    发明申请
    SYNTHETIC SENESCENT CELL ANTIGEN 审中-公开
    合成敏感细胞抗原

    公开(公告)号：WO1991018013A1

    公开(公告)日：1991-11-28

    申请号：PCT/US1991003557

    申请日：1991-05-24

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  KAY, Marguerite, M., B. ,  MARCHALONIS, John, J.

    IPC: C07K07/00

    CPC classification number: C07K14/705 ,  A61K38/00

    Abstract: Disclosed herein is a synthetic senescent cell antigen comprised of purified peptides immunoreactive with antibodies to the naturally occurring antigen. Preferably, the synthetic senescent cell antigen comprises two peptides with the amino acid sequences SKLIKIFQDHPLQKTYN and LFKPPKYHPDVPYVKR, respectively. The antigen and peptides may be used in compositions, diagnostic kits, and methods for detecting or measuring antibodies to senescent cell antigen, studying cellular aging and autoimmune mechanisms, separating anions from a gas or liquid, or treating certain diseases.

    TRYPANOSOMAL IMMUNOSUPPRESSIVE FACTOR
    75.
    发明申请
    TRYPANOSOMAL IMMUNOSUPPRESSIVE FACTOR 审中-公开
    TRYPANOSOMAL免疫抑制因子

    公开(公告)号：WO1991017759A1

    公开(公告)日：1991-11-28

    申请号：PCT/US1991003122

    申请日：1991-05-10

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  KIERSZENBAUM, Felipe ,  SZTEIN, Marcelo, B.

    IPC: A61K37/02

    CPC classification number: C07K14/44 ,  A61K38/00 ,  C07K16/20 ,  Y02A50/414

    Abstract: The present invention comprises a purified proteinaceous molecule (IL-2R inhibitor) derived from T. cruzi, said proteinaceous molecule having activity as an inhibitor of IL-2R expression. The present invention also comprises a partially purified proteinaceous molecule, compositions of matter containing such proteinaceous molecule and proteinaceous molecules substantially homologous to the T. cruzi derived IL-2R inhibitor. The invention also relates to pharmaceutical compositions and reagents utilizing such IL-2R inhibitors and compositions for immunologic studies.

    Abstract translation: 本发明包括衍生自克氏锥虫的纯化蛋白质分子（IL-2R抑制剂），所述蛋白质分子具有作为IL-2R表达抑制剂的活性。 本发明还包括部分纯化的蛋白质分子，含有这种蛋白质分子的物质组合物和与克氏锥虫来源的IL-2R抑制剂基本上同源的蛋白质分子。 本发明还涉及使用这种IL-2R抑制剂的药物组合物和试剂以及用于免疫学研究的组合物。

    SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION
    76.
    发明申请
    SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION 审中-公开
    酪氨酸，CYSTEINE和谷氨酰胺的总体营养可溶性和稳定来源

    公开(公告)号：WO1991016067A1

    公开(公告)日：1991-10-31

    申请号：PCT/US1991002777

    申请日：1991-04-23

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  HILTON, Mary, A.

    IPC: A61K37/02

    CPC classification number: A61K9/0029 ,  A61K31/195

    Abstract: The present invention provides soluble and/or stable sources of tyrosine, cysteine and glutamine for use in total parenteral nutrition (TPN), as well as a gradual release source of glutamic acid. In particular, these sources are gamma-glutamyltyrosine ( gamma -GluTyr), gamma-glutamylcysteine derivatives ( gamma -GluCys) and gamma-glutamylglutamine ( gamma -GluGln). This invention provides TPN formulations, and methods of formulating and using such solutions containing gamma -GluTyr, gamma -GluCys and/or gamma -GluGln to provide adequate nutritional levels of tyrosine, cysteine or glutamine during TPN.

    Abstract translation: 本发明提供用于全胃肠外营养（TPN）的酪氨酸，半胱氨酸和谷氨酰胺的可溶性和/或稳定来源，以及谷氨酸的逐渐释放来源。 特别地，这些来源是γ-谷氨酰酪氨酸（γ-Glulu），γ-谷氨酰半胱氨酸衍生物（γ-GluSys）和γ-谷氨酰谷氨酰胺（γ-Glulu）。 本发明提供TPN制剂，以及在TPN期间配制和使用含有γ-Glulu，γ-GluCys和/或γGluGln的溶液以提供足够的营养水平的酪氨酸，半胱氨酸或谷氨酰胺的方法。

    TOPICALLY ACTIVE OCULAR THIADIAZOLE SULFONAMIDE CARBONIC ANHYDRASE INHIBITORS
    77.
    发明申请
    TOPICALLY ACTIVE OCULAR THIADIAZOLE SULFONAMIDE CARBONIC ANHYDRASE INHIBITORS 审中-公开
    主要有效的OCARAR THIADIAZOLE SULFONAMIDE碳氢化合物抑制剂

    公开(公告)号：WO1991014430A1

    公开(公告)日：1991-10-03

    申请号：PCT/US1991001795

    申请日：1991-03-18

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  PIERCE, William, Jr.

    IPC: A61K31/41

    CPC classification number: C07D285/135 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

    Abstract: A compound of formula (I) or pharmaceutically acceptable salts thereof wherein R is hydrogen or lower alkyl; Y is (A'); X is O, S, NR6 or N; XY taken together is (B'); R2 is OR4, SR4, or NR4R5 represents a covalent bond connecting its adjacent carbonyl with X when X is N, thereby forming a cyclic imide of formula (II); R15 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocyclic or heterocyclic lower alkyl, wherein the heterocyclic group is an oxygen, nitrogen or sulfur containing heterocycle containing from 5 to 14 ring atoms or R15 represents a covalent bond connecting its adjacent carbinol with X when Y is N, thereby forming a cyclic diol of formula (III), M is -(CHR9)p, HC = C-(CHR9)q, -CH = CR9, (C') or (D'); Z is hydrogen or lower alkyl or a covalent bond; ring A is an alicyclic, aromatic ring or oxygen, nitrogen or sulfur containing heterocyclic or heteroaromatic ring, contains from 5 to 14 ring atoms and may be unsubstituted or substituted with at least one substituent selected from the group consisting of lower alkyl, aryl, aryl lower alkyl, carboxy, OH, carbolower alkoxy, formyl, lower alkanoyl, OH, SR3 or NR3R7; R3, R7 and R6 are independently hydrogen or lower alkyl; R4 and R5 are independently H, lower alkyl, aryl or aryl lower alkyl; each R9 can be the same or different and is H, lower alkyl, aryl, aryl lower alkyl, OR10, SR10 or NR10R11; each R10 and R11 can be the same or different and is H, lower alkyl, aryl, aryl lower alkyl, lower alkanoyl or aroyl; R14 is H or lower alkyl or R14 and Z taken together form a covalent bond; p is 0-6; q is 0-4; and n is 0 or 1.

    Abstract translation: 式（I）化合物或其药学上可接受的盐，其中R是氢或低级烷基; Y是（A'）; X为O，S，NR 6或N; XY一起是（B'）; 当X是N时，R2是OR4，SR4或NR4R5表示连接其相邻羰基与X的共价键，从而形成式（II）的环状酰亚胺; R 15为氢，低级烷基，低级烯基，低级炔基，芳基，芳基低级烷基，杂环或杂环式低级烷基，其中杂环基为含有5至14个环原子的含氧，含氮或含硫杂环或R 15表示共价 当Y为N时，将其相邻的甲醇与X连接，从而形成式（III）的环状二醇，M为 - （CHR 9）p，HC = C-（CHR 9）q，-CH = CR 9，（C'）或 （D'）; Z是氢或低级烷基或共价键; 环A是脂环族，芳香环或含氧，氮或硫的杂环或杂芳环，含有5至14个环原子，并且可以是未取代的或被至少一个选自以下的取代基取代：低级烷基，芳基，芳基 低级烷基，羧基，OH，羧甲基烷氧基，甲酰基，低级烷酰基，OH，SR3或NR3R7; R3，R7和R6独立地是氢或低级烷基; R4和R5独立地是H，低级烷基，芳基或芳基低级烷基; 每个R 9可以相同或不同，为H，低级烷基，芳基，芳基低级烷基，OR 10，SR 10或NR 10 R 11; 每个R 10和R 11可以相同或不同，为H，低级烷基，芳基，芳基低级烷基，低级烷酰基或芳酰基; R 14是H或低级烷基或R 14和Z一起形成共价键; p为0-6; q为0-4; n为0或1。

    METHOD AND APPARATUS FOR IMPLEMENTING POST-MODULATION ERROR CORRECTION CODING SCHEME
    78.
    发明申请
    METHOD AND APPARATUS FOR IMPLEMENTING POST-MODULATION ERROR CORRECTION CODING SCHEME 审中-公开
    用于实施调制后错误校正编码方案的方法和装置

    公开(公告)号：WO1991011059A1

    公开(公告)日：1991-07-25

    申请号：PCT/US1991000032

    申请日：1991-01-09

    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

    Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  FITINGOF, Boris ,  MANSURIPUR, Masud

    IPC: H03M13/00

    CPC classification number: G11B20/10055 ,  G11B20/1426 ,  G11B20/1809

    Abstract: A method of and apparatus for providing error correction coding for a block of user data is disclosed in which the user data (101) is initially modulated by a first modulator (102) and then the modulated user data (108) is error correction encoded to produce a first plurality of check bits (106). The first plurality of check bits are then modulated by a second modulator (114) whose output is then fed to a second error correction (120) which produces a second plurality of check bits (118). The modulated user data, the first plurality of check bits and the second plurality of check bits are all fed to a shift register (128) where the error correction encoded user data block is formed. The present invention is useful with magnetic and optical storage devices.

Patent Agency Ranking